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OBJECTIVE: To assess the economic effect and cost effec-
tiveness of a targeted catheter-associated urinary tract
infection (CAUTI) prevention intervention in the nursing
home (NH) setting.
DESIGN: Randomized clinical trial.
SETTING: Community-based NHs (N512).
PARTICIPANTS: NH residents with indwelling urinary
catheters (N5418).
INTERVENTION: Standard care versus infection preven-
tion program involving barrier precautions, active surveil-
lance, and NH staff education.
MEASUREMENTS: Costs of the intervention, costs of
disease, and health outcomes were used to calculate an
incremental cost-effectiveness ratio for the intervention.
Data came from intervention results and the literature and
outcomes were analyzed over one year.
RESULTS: A 120-bed NH would have program costs of
$20,279/year. The cost of disease treatment would be
reduced by $54,316 per year, resulting in a $34,037 net
cost savings. Most of this savings would come from fewer
CAUTI hospitalizations ($39,180), with $15,136 in sav-
ings from CAUTI care within the NH. The intervention
also yielded a gain of 0.197 quality-adjusted life-years
(QALYs). Taking into account uncertainty in all parame-
ters suggests there is an 85% chance that the intervention
is cost-saving.
CONCLUSIONS: The CAUTI prevention program is
expected to benefit payers by reducing costs and improv-
ing health outcomes. Because the savings accrue to payers
and not to NHs, payers such as Medicare and private
insurers may want to provide incentives for NHs to imple-
ment such programs.
TRIAL REGISTRATION: clinicaltrials.gov Identifier:
NCT01062841 J Am Geriatr Soc 66:742–747, 2018.
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A t any given time, there are more people in nursinghomes (NHs) in the United States than in hospitals,
making NHs a crucial part of the healthcare system.1
Because NHs have a predominantly frail older population
with a high acuity of illness, nosocomial infections are
common and often severe in NHs, resulting in frequent
hospital transfers and an estimated $2 billion in hospital
expenditures per year.2
NH residents at risk of infection share several charac-
teristics, including indwelling devices, prior antimicrobial
usage, recent hospitalization, and functional impair-
ment.3,4 Recent national data show that approximately
12% to 15% of individuals newly admitted to a NH have
an indwelling urinary catheter and that 5% to 10% have
a chronic urinary catheter.5,6 Thus, on any given day,
80,000 to 150,000 of the 1.5 million NH residents have
an indwelling urinary catheter.7 Unlike acute care settings
with shorter lengths of stay, even appropriately placed uri-
nary catheters in NH residents often remain in place for
prolonged periods, with an average duration of 105 days.8
These catheters are responsible for the largest institutional
reservoir of multidrug-resistant organisms (MDROs), and
their presence doubles the risk of symptomatic infec-
tions.3,9 More than half of episodes of fever in individuals
with chronic indwelling urinary catheters are from a uri-
nary source, with an incidence of approximately 1 per 100
catheterized resident-days.3 Some of these catheter-
associated urinary tract infections (CAUTIs) will lead to
bacteremia, sepsis, and death.3,4 The Centers for Medicare
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and Medicaid Services (CMS) recent reform of the require-
ments for nursing facilities requires that facilities have an
infection prevention and control program and designate
an infection preventionist. The estimated cost of this infec-
tion control preventionist is expected to be $19,032 per
facility per year.10 CMS does not have an estimate of the
benefits of this type of program.
In a recent interventional study, we evaluated the
effectiveness of a 3-year targeted infection prevention
(TIP) multimodal intervention program in reducing
MDRO prevalence and device-associated infections in a
group of 12 NHs in southeast Michigan.8 The intervention
included a structured interactive educational program for
NH staff, hand hygiene promotion, preemptive barrier
precautions when assisting with high-risk activities of daily
living, and active surveillance for MDROs and infections,
with an infection preventionist supporting monthly data
feedback. This intervention led to a 23% reduction in
overall MDRO prevalence density rate and a 31% reduc-
tion in all clinically diagnosed CAUTIs.8 In addition, we
documented 30% fewer hospitalizations of residents with
CAUTIs.8 To further enhance the usefulness of our find-
ings, we sought to determine whether the targeted inter-
vention was cost effective for an average NH. Previous
studies reporting on the effectiveness of CAUTI reduction
interventions in hospital settings have showed cost reduc-
tions and significant decreases in morbidity,11–13 but few
studies have included cost-effectiveness analyses to make a
business case to devote resources to infection-prevention
programs in NHs and other long-term care settings.14–16
Our primary aim was to examine the economic effect of
our intervention program.
METHODS
We used a cost-effectiveness analysis framework. Our goal
was to determine whether the benefits from the TIP inter-
vention program exceeded the costs and, if not, how much
was being paid per unit of health outcome gained. This ret-
rospective analysis of the program was conducted to assist
NH administrators and policy-makers in evaluating its suc-
cess and to facilitate future implementation. This TIP study
is a multicenter randomized clinical trial evaluating a multi-
modal, practical, evidence-based program to reduce CAUTIs
in nursing homes.8 This cluster-randomized study, which
the University of Michigan institutional review board
approved, was conducted in 12 (6 control, 6 intervention)
community-based NHs in Michigan. Intervention and con-
trol sites had similar infection prevention programs at base-
line.8 The intervention took place over 3 years. Although
only approximately half of residents with indwelling devices
at the NHs provided consent and were enrolled in the pro-
gram, we predict that the benefits of the intervention will
apply to the care of all NH residents at the facility, including
short- and long-stay residents.
We conducted the cost-effectiveness analysis from the
healthcare system perspective. We examined the effect of
the intervention at a representative NH over 1 year,
applying reductions in adverse events observed in the trial
to all residents with indwelling urinary catheters. The
intervention resulted in a reduction of CAUTIs from 9.2
per 1,000 device-days to 5.9 per 1,000 device days.8 There
were 3.7 hospitalizations for CAUTIs per 1,000 device-
days in controls and 2.6 per 1,000 device days in interven-
tion participants.8 These outcomes are modeled in this
analysis and affect costs and quality-adjusted life-years
(QALYs) lost (Figure 1).
In addition to the base-case cost-effectiveness analysis,
costs and outcomes were calculated from the perspective of
just the NH (ignoring costs outside the NH such as hospital-
ization) to assess how the intervention might affect the NH
alone. Only the costs of the intervention and the costs of
health outcomes that the intervention affected were used in
our calculations; the costs of standard NH care were not
included and were assumed to be equal for the intervention
and control NHs (Table 1). Costs and outcomes were calcu-
lated for a representative 120-bed NH with 6% of residents
having indwelling urinary catheters,5 using the annual rates
observed over the 3-year intervention and applied to all resi-
dents with indwelling urinary catheters.
Intervention Costs
All costs are expressed in 2015 U.S. dollars. The interven-
tion costs include the cost of an infection prevention spe-
cialist to lead and oversee the intervention program,
nursing personnel costs to attend educational activities,
nursing time for donning protective equipment, supplies
for hand hygiene activities and barrier precautions, and
interactive educational materials (Table 1). We did not
include costs of active surveillance for MDROs, which
were used for research evaluation purposes. Resource use
for the 6 intervention NH sites were evenly divided to cal-
culate per-NH resource use. Additional details on the cal-
culations of these intervention costs are in Supplemental
Appendix S1.
Figure 1. Schematic of decision tree model. The figure should
be read from left to right. The square represents the interven-
tion decision. Circles represent uncertain outcomes for nurs-
ing home residents: whether they develop a catheter-
associated urinary tract infection (CAUTI), whether they are
hospitalized, and whether they have septicemia, given
hospitalization.
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Disease Costs
The cost of CAUTI treatment in a NH, the cost of hospi-
talization for a CAUTI, and the cost of hospitalization for
CAUTI-associated septicemia were incorporated into the
disease cost analysis.17–20 The cost of CAUTI treatment in
a NH was estimated to be $1,745 per infection episode.21
The Office of the Inspector General of the Department of
Health and Human Services has reported on the costs spe-
cifically related to hospitalizations from NHs, reporting
that the average cost of hospitalization for a CAUTI was
$13,554 in 2011 and that the cost of hospitalization for
septicemia was reported to be $19,914 per episode.18 A
weighted average of the cost of hospitalization for a
CAUTI and the cost of hospitalization for CAUTI-related
septicemia was used to calculate the overall average cost
of CAUTI care in a hospital. We assumed that half of NH
hospitalizations for CAUTI had a primary diagnosis of
septicemia (Table 1).20 Additional details on hospitaliza-
tion cost calculations can be found in Supplemental
Appendix S1. Because NH residents are usually not
employed, opportunity costs of infection and hospitaliza-
tion were not included.
Utilities
The health outcomes of the intervention were calculated in
terms of QALYs lost related to CAUTI (Table 2). Utility
scores were taken from the literature.22–24 These studies
averaged utilities over a mix of residents who were hospital-
ized and not hospitalized. The utility score decrement during
the course of a CAUTI was estimated to be 0.09, and the
average duration of a CAUTI was estimated to be 14 days in
the base case.23,24 Long-term utility loss for a CAUTI was
estimated to be 0.02.22 The long-term utility loss was
assumed to occur for the remainder of the year.
Evaluating the Value of the TIP Intervention Program
If the TIP intervention program results in lower NH costs
and fewer QALYs lost from disease than in the control
group, it is said to be cost saving. In that case, we
recorded the costs saved and QALYs gained. In the case in
which the TIP intervention would lead to higher costs and
fewer QALYs lost than in the control group, the impor-
tant consideration is whether the QALYs saved are worth
the extra cost. In that case, we computed an incremental
Table 1. Input Parameters
Parameter Base Minimum Maximum Source
Intervention effectiveness
Residents with catheter, % 6 5 7 Rogers et al. 5
Clinically defined CAUTI per 1,000 days of catheter use
Control 9.2 7.38 11.57 Mody et al.8
Intervention 5.9 4.59 7.72 Mody et al.8
Hospitalizations per 1,000 days of catheter use
Control 3.7 2.60 5.28 Mody et al.8
Intervention 2.6 1.76 3.85 Mody et al.8
Intervention cost parameters
Full-time equivalents required 0.21 0.17 0.25 Mody et al.8
Infection control annual salary, $ 55,000 41,250 68,750 Mody et al.8
Educational activities
Nurse hourly wages, $ 32 24 40 Mody et al.8
Nurse hours for intervention training 16.67 12.50 20.83 Mody et al.8
Nursing aide hourly wages, $ 12 9 15 Mody et al.8
Nursing aide hours for intervention training 50 37.50 62.50 Mody et al.8
Additional resident time
Gown and glove donning time (minutes) per resident
visit for intimate activities of daily living (with indwelling device)
0.63 0.27 1.00 Martin et al.17
Resident visits for intimate activities of daily living per day 6.00 4.00 8.00 Assumption
Supplies, $ 2,000 1,500 2,500 Mody et al.8
Printing, $ 361 271 451 Mody et al.8
Costs of disease, $
Cost of CAUTI in nursing home 1,745 1,500 2,000 Maki et al.21
Cost of hospitalization
Cost of hospitalization due to CAUTI 7,193 5,395 8,992 OIG report19
Cost of hospitalization from septicemia 19,914 14,936 24,893 OIG report19
Fraction of CAUTI leading to septicemia 0.5 0.25 0.75 OIG reports18,19
Utilities
Length of CAUTI symptoms 14 7 14 Hout et al. 22
Utility loss per CAUTI 0.09 0.04 0.14 Maxwell et al.24
Long-term utility loss due to CAUTI 0.02 0 0.05 Hout et al.22
The Base column contains values used for the base case analysis. The Minimum and Maximum columns are used for sensitivity analysis. In the probabilis-
tic sensitivity analysis, the parameters are assumed to be normally distributed, with the base representing the mean, and the minimum and maximum rep-
resenting a 4–standard deviation spread (roughly 95% of the distribution). Additional details on how these parameters were calculated are in the
supplemental text.
CAUTI 5 catheter-associated urinary tract infection.
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cost-effectiveness ratio (ICER) defined as: (cost of inter-
vention—cost of control) / (QALYs lost with control–
QALYs lost with intervention). We have included the
Consolidated Health Economic Evaluation Reporting
checklist (Supplemental Appendix S1) to help readers
understand and find many of the details of this analysis.
Sensitivity Analysis
We conducted univariate sensitivity analysis on all varia-
bles in our model and conducted a probabilistic sensitivity
analysis using Monte Carlo simulation to simultaneously
vary parameter assumptions to quantify overall uncer-
tainty in the results in cost-effectiveness acceptability
curves. Assumptions about the variability of the parame-
ters used for the univariate and probabilistic sensitivity
analyses are shown in Table 1.
RESULTS
Base-Case Analysis
Our analyses show that the implementation of a TIP inter-
vention program would lead to 8.7 fewer CAUTIs and 2.9
fewer resident hospitalizations per NH per year. The inter-
vention would cost $20,279 for the NH over the course of
a year, with disease costs under the intervention of
$119,669, for a total of $139,948. This is lower than the
$173,986 in disease costs for the control group in the TIP
study. The intervention saved $15,136 in NH CAUTI care
and $39,180 in hospital care for CAUTIs and CAUTI-
associated septicemia, for a total net savings of $34,037
for the healthcare system, as well as 0.2 more QALYs
than in the control group (Table 2).
The intervention costs were estimated to be $11,458
for the time of an infection control specialist, $1,133 for
other staff in-service time, $5,326 for staff time donning
protective equipment, and $2,361 in supplies and printing.
The largest costs were disease-related costs. A majority of
the costs were for CAUTI care in a hospital. If the NH
was responsible for the costs of the intervention and
CAUTI care within the NH but not for costs of CAUTI
care in the hospital, the NH would have a net cost
increase of $5,143.
Sensitivity Analysis
We first varied all input parameter assumptions one at a
time to see how they affected the value of the TIP inter-
vention program. The variables that most substantially
affected the costs saved were the rates of hospitalization
for CAUTIs (Supplemental Table S2). If the intervention
reduced the rate of hospitalizations from 3.7 to 3.55 per
1,000 device-days (9.7 per year to 9.3 per year for the
NH), the TIP intervention would be cost saving (Supple-
mental Figure S1). Taking into account uncertainty in all
parameter values simultaneously in the probabilistic sensi-
tivity analysis, we conclude that the TIP intervention is
85% likely to be cost saving and 96% likely to be cost
effective at a threshold of $200,000/QALY (Supplemental
Figure S2).
DISCUSSION
This cost-effectiveness analysis showed that the TIP inter-
vention program was expected to save $34,000 per year
and improve health outcomes by 0.2 QALYs. A systematic
review of the cost-effectiveness analysis literature showed
that only 20% of prevention interventions evaluated in
cost-effectiveness analyses are found to be cost saving,25
meaning that they improve health and reduce costs. Find-
ing interventions that are cost saving is difficult because
the right interventions must be applied in the correct set-
tings to the appropriate residents. The TIP program is one
of the few interventions that saves money and improves
health outcomes by reducing infections and related hospi-
talizations in a high-risk setting and population.
When viewed solely from the financial perspective of
the NH alone, the intervention may not appear to have
net cost savings. We show that a focused risk factor–based
intervention would cost the NH approximately $20,000
per year but result in approximately $15,000 in annual
savings from reduced CAUTI care in the NH, for a net
cost to the NH of approximately $5,000. Most of the ben-
efits to the overall healthcare system result from $40,000
of reduced CAUTI care in hospitals, which are savings
that payers probably capture. This suggests that payers,
who benefit the most from an intervention like TIP, may
find it financially worthwhile to provide incentives to
NHs to conduct similar infection control programs that
promote consistent application of evidence-based practices
in high-risk populations. CMS estimates that the cost of
its new broad infection control program would be
$19,032 per NH per year, which is a significant underesti-
mation because it includes only the cost of the infection
preventionist.10 In addition, CMS fails to account for the
benefits to the NH and the health system of the reduced
infections and hospitalizations.10
These findings should be placed in context with recent
infection prevention initiatives in other healthcare settings.
A systematic review of hospital-based infection prevention
interventions found 7 recent studies in the United States
evaluating the net economic effect of the programs.26 All
Table 2. One-Year Health and Cost Outcomes for a
Representative 120-Bed Nursing Home
Outcome Intervention Control
Health
CAUTI (events) 15.5 24.2
Hospitalizations due to CAUTI (events) 6.8 9.7
Quality-adjusted life-years lost from CAUTI 0.35 0.55
Costs, $
Intervention costs 20,279 0
Disease costs
CAUTI care in nursing home 27,061 42,197
CAUTI care in hospital 92,608 131,789
Disease subtotal 119,669 173,986
Total costs 139,948 173,986
Interpretation Cost savings of 34,037
CAUTI 5 catheter-associated urinary tract infection.
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7 found that the programs had cost savings in excess of
intervention costs. Since that review was conducted, sev-
eral additional studies have been published.27–29 A recent
study27 of a multifaceted quality improvement program to
reduce central line–associated bloodstream infections in
intensive care units (ICUs) found that the intervention pre-
vented 42 central line-associated bloodstream infections
and 6 deaths and saved $249,000 per 1,000 patients.
Another study28 of infection precautions to prevent
methicillin-resistant Staphylococcus aureus (MRSA) trans-
mission in U.S. ICUs found that universal decolonization
would prevent 246 infections and save $2.81 million per
10,000 ICU admissions and that universal contact precau-
tions plus decolonization would prevent an additional 66
infections per 10,000 admissions at a cost of $9,007 per
incremental infection prevented. In a third study,29 an
evaluation of multifaceted infection prevention programs
designed to decrease central line–associated bloodstream
infections and ventilator-associated pneumonia in ICUs
found that the intervention improved health and saved ini-
tial inpatient costs, but even though long-term costs
increased (partially because of longer life expectancy after
discharge), the intervention was still cost effective, at
$23,278/QALY gained. These studies provide evidence
that multifaceted programs to reduce infections in health-
care settings can be cost saving or cost effective, but they
were all in ICU settings. Our results build on this evidence
and show that, in a NH setting, similar interventions can
be cost saving and improve health outcomes for NH
residents.
Our study has several limitations. In the analysis of a
representative NH, we assumed that NH residents who
did not consent to participate in the TIP intervention pro-
gram would have similar reductions in rates of CAUTI.
We felt this was a reasonable assumption, given that the
program was geared toward all residents. Furthermore,
the intervention in the trial included active surveillance for
MDROs to evaluate study outcomes. Because this is nei-
ther practical for a typical NH nor the current standard of
care, we did not include that as part of the cost-
effectiveness analysis, although it is possible the active sur-
veillance may have had an additional effect on the study
results.
The analysis may also have underestimated the effect
of CAUTI prevention in several ways. First, although the
results indicated a reduction in MRSA colonization, we
did not incorporate these costs into the analysis because
we had limited information on the cost effectiveness of
preventing MRSA colonization. Presumably, though, the
decrease in colonization of pathogens should lead to fewer
infections in NH populations and would extend the cost
savings of this program. Second, we did not evaluate the
benefits of reduction in MDRO transmission to other NH
residents, which could lead to further infection reductions
in MDROs, as well as other pathogens. It is possible that
reductions in infections could also lead to reductions in
mortality, although the study was not powered to detect
differences in mortality, so we did not include it as an out-
come measure. This may have led to an underestimate of
the benefits of the intervention. Finally, we did not mea-
sure the effect of this type of intervention on other aspects
of broad-based infection prevention. For example, greater
adherence to hand hygiene guidelines may reduce overall
nosocomial infections in NH residents without indwelling
urinary catheters.
This study also has several strengths. Our results are
based on a randomized, controlled intervention study of
12 NHs in southeast Michigan. We believe the results are
generalizable to other NH populations. The intervention
was comprehensive and designed to affect all NH resi-
dents, not just those at high risk. We evaluated the results
from several perspectives and found that the multicompo-
nent intervention may be viewed differently from the per-
spective of the NH itself and that of the payer and the
healthcare system as a whole. Because the program is
expected to have a net cost to the NH (cost of the pro-
gram outweigh CAUTI savings within the NH), there may
be a need to provide incentives to NHs to enact these
types of interventions. The overall benefits to the health
system of infection prevention interventions along with the
benefits to payers provide sufficient value and cost benefits
to be shared with NHs. In addition, new organizational
structures such as accountable care organizations may be
ideal platforms to align incentives between NHs, hospitals,
residents, and payers because these organizations may
share benefits and savings. NHs that implement these
types of interventions may be more attractive to hospitals
looking for preferred locations for postacute care in their
networks.
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